Summary & Overview
HCPCS G8870: Hepatitis B Vaccine for Patients Starting Anti-TNF Therapy
HCPCS Level II code G8870 designates administration of the Hepatitis B vaccine for a patient who has previously received the vaccine and is undergoing a first course of anti-TNF therapy. This preventative measure is clinically significant because patients starting anti-TNF agents face increased infection risk and may require documented vaccination status and timely immunization prior to immunosuppression.
Key payers included in the discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication explains coverage considerations across major national payers, highlights common billing and documentation expectations, and outlines where benchmarks and policy updates typically affect reimbursement and prior authorization workflows.
Readers will find a concise explanation of the clinical context for G8870, typical sites of service, and the administrative role this code plays in pre-biologic therapy workflows. The report also summarizes available benchmarking practices and policy trends that influence how payers handle vaccine administration tied to initiation of anti-TNF therapy. Data not provided in the input are noted as unavailable; the focus remains on national relevance for clinicians, billing staff, and health plan analysts.
Billing Code Overview
HCPCS Level II code G8870 describes administration of the Hepatitis B vaccine for a patient who has previously received the vaccine and is receiving a first course of anti-TNF therapy. This code indicates vaccination activity tied specifically to initiation of anti-tumor necrosis factor treatment.
-
Service type: Vaccine administration related to initiation of immunomodulatory therapy
-
Typical site of service: Outpatient clinic, infusion center, or physician office where patients are assessed prior to starting anti-TNF biologic therapy
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient with active rheumatoid arthritis is scheduled to begin infliximab, a tumor necrosis factor (anti‑TNF) inhibitor. During the pre‑biologic evaluation visit in the outpatient rheumatology clinic, the clinician documents that the patient has not completed Hepatitis B immunization or has unknown immunity. Per protocol, the clinician administers the first dose of the hepatitis B vaccine series and documents that the vaccine was administered because the patient is initiating a first course of anti‑TNF therapy. The workflow includes review of prior immunization records, screening for hepatitis B surface antigen and surface antibody as indicated, counseling about vaccine series completion and timing relative to biologic therapy, administration of the vaccine, documentation in the medical record and immunization registry, and billing using the HCPCS Level II code G8870 for the hepatitis B vaccine administered in the context of starting anti‑TNF therapy. Typical sites of service are outpatient hospital-based infusion or clinic vaccination areas and ambulatory rheumatology or primary care offices; the service is often performed prior to or during the initial biologic therapy planning visit.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when a distinct E/M visit is documented on the same day as vaccine administration and meets E/M criteria |